Cognition Therapeutics Inc (CGTX)

12:28 PM

What analysts say about Cognition Therapeutics Inc. stockRemarkable growth - Autocar Professional

12:28 PM

Jul 22, 2025

What drives Cognition Therapeutics Inc. stock priceDynamic growth stocks - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is Cognition Therapeutics Inc. a good long term investmentUnbelievable profit margins - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire

Jul 21, 2025

Jul 21, 2025

Cognition Therapeutics reports positive results for Alzheimer’s drug - Investing.com India

Jul 21, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq

Jul 21, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times

Jul 21, 2025

Jul 21, 2025

Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan

Jul 21, 2025

Jul 20, 2025

Cognition Therapeutics Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional

Jul 20, 2025

Jul 19, 2025

How high can Cognition Therapeutics Inc. stock price go in 2025Capital Efficient Investment Tips - beatles.ru

Jul 19, 2025

Jul 17, 2025

Dementia Associated with Alzheimer’s Disease Drug - GlobeNewswire

Jul 17, 2025

Jul 16, 2025

Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com

Jul 16, 2025

Jul 16, 2025

Cognition Therapeutics stock soars after DLB study results - Investing.com

Jul 16, 2025

Jul 16, 2025

Cognition Therapeutics stock soars after DLB study results By Investing.com - Investing.com South Africa

Jul 16, 2025

Jul 16, 2025

CGTX Soars 19.72% on Promising Dementia Drug Results - AInvest

Jul 16, 2025

Jul 16, 2025

Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq

Jul 16, 2025

Jul 16, 2025

Cognition Therapeutics' Positive Clinical Data from - GlobeNewswire

Jul 16, 2025

Jul 16, 2025

Breakthrough DLB Treatment: Clinical Trial Reveals 86% Symptom Improvement in Dementia Patients - Stock Titan

Jul 16, 2025

Jul 16, 2025

Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com

Jul 16, 2025

Jul 15, 2025

How Cognition Therapeutics Inc. stock performs during market volatilityMomentum Buy Alert - Newser

Jul 15, 2025

Jul 15, 2025

Why Cognition Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser

Jul 15, 2025

Jul 15, 2025

What makes Cognition Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser

Jul 15, 2025

Jul 15, 2025

Cognition Therapeutics shares fall 1.16% premarket after Karolinska Development's portfolio company Umecrine Cognition raises SEK 24.6 million for clinical development. - AInvest

Jul 15, 2025

Jul 14, 2025

CGTX’s 2025 Market Saga: Unraveling the Story of Gains and Losses - investchronicle.com

Jul 14, 2025

Jul 12, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of “Buy” from Analysts - Defense World

Jul 12, 2025

Jul 12, 2025

Cognition Therapeutics (NASDAQ:CGTX) Rating Lowered to Strong Sell at Wall Street Zen - Defense World

Jul 12, 2025

Jul 11, 2025

Cognition Therapeutics: Clinical Milestones Ignite Potential in Neurodegenerative Therapeutics - AInvest

Jul 11, 2025

Jul 11, 2025

Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress - Yahoo Finance

Jul 11, 2025

Jul 11, 2025

Cognition Therapeutics, Inc. (CGTX) Plunges 14.29% Amid FDA Meeting Outcome - AInvest

Jul 11, 2025

Jul 11, 2025

Cognition Therapeutics shares fall 10.57% in premarket after FDA meeting on zervimesine for Alzheimer's treatment. - AInvest

Jul 11, 2025

Jul 11, 2025

Cognition Therapeutics completes FDA end-of-Phase 2 meeting for Alzheimer’s drug By Investing.com - Investing.com South Africa

Jul 11, 2025

Jul 10, 2025

Cognition Therapeutics Inc. (CGTX) Soars 31.45% on FDA Phase 3 Trial Approval - AInvest

Jul 10, 2025

Jul 10, 2025

Cognition Therapeutics completes FDA end-of-Phase 2 meeting for Alzheimer’s drug - Investing.com Nigeria

Jul 10, 2025

Jul 10, 2025

Cognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesine - Seeking Alpha

Jul 10, 2025

Jul 10, 2025

Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug - Investing.com

Jul 10, 2025

Jul 10, 2025

Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug By Investing.com - Investing.com South Africa

Jul 10, 2025

Jul 10, 2025

Cognition Therapeutics Conducts Meeting With US FDA to Review Phase 2 Study Results of Zervimesine - MarketScreener

Jul 10, 2025